Australia's Mesoblast extends gains on upbeat Ryoncil cell therapy earnings

Mesoblast

13/07/2026 01:47

** Shares of Mesoblast MSB.AX extend gains, rising as much as 9.4% to A$2.45, their highest level since February 27 
** Stock marks biggest intraday pct jump since March 5, making it the top gainer on the broader benchmark .AXJO
** Drugmaker on Friday said its cell therapy Ryoncil booked qtrly net revenue of $36 million, up from $30.3 million in prvs qtr
** Stock down 11.8% YTD, including the day's moves

 (Reporting by Sneha Kumar in Bengaluru)
 ((Sneha.kumar@thomsonreuters.com;))